|
Since
2006, 23andMe’s mission has been to help people access,
understand, and benefit from the human genome. We are a group
of passionate individuals pushing the boundaries of what’s
possible to help turn genetic insight into better health and
personal understanding.
23andMe has amassed an incredible data resource for genetics
and epidemiology research. With more than 12 million genotyped
individuals and 10 billion phenotypic data points, we offer a
true playground for discovery. Our Postdoctoral Fellowship
program provides a fully funded opportunity to analyze and
publish findings from cutting-edge explorations of this unique
database. In the past, our postdocs have published on topics
as diverse as historical genomes, Parkinson’s disease, and
race/ethnicity in genetic research. We offer dedicated
mentorship, opportunities to present at scientific meetings,
and a chance to explore a career in the industry while still
engaging in academic research and building a publication track
record.
Postdoctoral Fellow, COVID-19
Since the start of the pandemic, 23andMe has emerged as a
leader in understanding genetic and environmental
contributions to COVID-19 risk. To date, over 1.5 million
individuals have completed our COVID-19 baseline survey,
and over 105K have completed our long COVID survey.
While we have already published our genetic findings for
COVID-19 susceptibility in top level journals (Nature
Genetics), there is more to discover. As the pandemic enters
this new stage, the focus of the scientific and clinical
community shifts to “long COVID”-- chronic, often debilitating
sequelae of the acute infection. We currently have in-depth
symptomology and disease severity data on tens of thousands of
long COVID cases. Due to the chronic nature of long COVID and
potential application to other post-viral illnesses--
including many “mystery diagnoses” in the immune space-- this
area of inquiry could be a fruitful source of descriptive and
genetic discoveries.
23andMe is looking to hire a Postdoctoral Fellow who is
excited to explore these data with us! This is an internally
funded, two-year position situated within the Research team
and co-mentored by scientists from our Research and
Therapeutics teams. There is an emphasis on teamwork,
engagement with the broader scientific community, professional
growth, and ability to promptly deliver results.
What You’ll Do
| |
i |
Publish peer-reviewed articles, blog posts, and conference
abstracts on topics relevant to long COVID
and other chronic sequelae of immune infections, e.g.:
|
| |
|
♦ |
Describing the epidemiology/natural history/symptomology of
COVID-19 (including “long COVID”) in the 23andMe database
|
| |
|
♦ |
Deeper understanding observed disparities in long/severe
COVID-19 risk (e.g. excess risk in certain
communities/demographic groups that is not explained by
genetic or measured non-genetic determinants)
|
| |
|
♦ |
Modeling genetic and environmental determinants of COVID-19
infection and sequelae, as well as of breakthrough infections;
exploring effect measure modification by strain
|
| |
|
♦ |
Identifying phenotypic overlap with other immune diseases and
potentially novel disease subtypes/clusters
|
What You’ll Bring
| |
i |
PhD in Epidemiology, Biostatistics, or a related discipline
(Systems Biology, Applied Mathematics, Bioinformatics, Data
Science, Immunology, and others)
|
| |
i |
Statistical analysis (exploratory data analysis, regression
modeling, data visualization)
|
| |
i |
Scientific computing proficiency (R or Python, experience with
Shiny/R Markdown is a plus, Unix)
|
| |
i |
Scientific communication skills (to write up and share the
results) |
Please send your resume and apply via this link:
https://grnh.se/88c090872us
About Us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer
genetics and research company. Founded in 2006, the company’s
mission is to help people access, understand, and benefit from
the human genome. 23andMe has pioneered direct access to
genetic information as the only company with multiple FDA
authorizations for genetic health risk reports. The company
has created the world’s largest crowdsourced platform for
genetic research, with 80 percent of its customers electing to
participate. The platform also powers the 23andMe Therapeutics
group, currently pursuing drug discovery programs rooted in
human genetics across a spectrum of disease areas, including
oncology, respiratory, and cardiovascular diseases, in
addition to other therapeutic areas. More information is
available at www.23andMe.com.
|
